Perception Neuroscience

Employee Size

2-10

Organization Type

Privately Held

Headquarters

New York, NY

Founded

2018

Perception Neuroscience is a New York City-based clinical-stage biopharmaceutical company developing PCN-101, an R-ketamine compound intended to provide faster-acting treatment options for serious psychiatric disorders. The company holds an exclusive license to intellectual property originating from research at Japan’s Chiba University and has advanced PCN-101 through Phase 1 studies and an FDA-cleared IND into Phase 2 clinical development. Perception is majority-owned by atai Life Sciences and partnered with Otsuka Pharmaceutical on development in Japan.

• Gilgamesh PharmaGilgamesh Pharma is a New York clinical-stage neuroscience biotech developing novel chemical entities for psychiatric disease, with an emphasis on rapid-acting and durable therapies rather than symptom management alone. Its in-house discovery platform combines medicinal chemistry, neurocircuitry science, and computational modeling, and has produced clinical programs including blixeprodil and a neuroplastogen partnership with AbbVie. The company’s first clinical asset, bretisilocin, was acquired by AbbVie after advancing to Phase 2.New York, NY
• Kannalife Sciences, IncFounded in 2010 and based at the Pennsylvania Biotechnology Center in Doylestown, Kannalife Sciences develops patented synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead investigational molecule, KLS-13019, is being advanced as a potential non-opioid treatment for chemotherapy-induced peripheral neuropathy, with research also examining Parkinson’s disease and other conditions linked to oxidative stress. Kannalife is a wholly owned Neuropathix subsidiary whose scientific team reports more than 75 years of combined pharmaceutical research experience and over 65 jointly held patents.DOYLESTOWN, PA
• Neuropathix, IncFounded in 2010 through the creation of Kannalife Sciences, Neuropathix develops synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead compound, KLS-13019, is a globally patented non-opioid candidate being advanced from preclinical and IND-enabling research for chemotherapy-induced peripheral neuropathy, with research conducted at the Pennsylvania Biotechnology Center in Doylestown. The company’s scientific team brings more than 75 years of pharmaceutical research experience and holds more than 65 patents jointly.DOYLESTOWN, PA
• Supernus Pharmaceuticals, IncFounded by Jack A. Khattar in 2005, Supernus Pharmaceuticals is a Rockville biopharmaceutical company that develops and commercializes medicines for central nervous system diseases. With more than 30 years of product-development expertise, it uses proprietary technologies and an active clinical pipeline to advance treatments in neurology and psychiatry, while marketing its medicines in the United States through specialty sales forces.ROCKVILLE, MD